MDGL in the 13F filings
Madrigal Pharmaceuticals Inc · CUSIP 558868105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 28
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 8 listed it in both
- Shares listed
- 4,239,589
- combined, among listed positions
- Reported value
- $2.5bn
- combined, at the quarter end
Among the 92 comparable managers: 15 buyers (opened or added shares) and 13 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -143,709.
Managers listing MDGL in Q4 2025
28 of 28 holders
Largest increases and reductions, by shares
Increases
- Point72 Asset Management LPexisting position · 126,435 shares now+85,202
- Invesco Ltdexisting position · 365,314 shares now+65,749
- Wellington Management Group LLPexisting position · 461,402 shares now+56,947
- Squarepoint Ops LLCexisting position · 74,934 shares now+44,998
- Marshall Wace LLPexisting position · 39,578 shares now+38,878
Reductions
- Janus Henderson Group Ltdexisting position · 1,584,843 shares now-257,847
- Susquehanna International Group LLPexisting position · 64,466 shares now-40,352
- T. Rowe Price Associates Incexisting position · 313,659 shares now-38,861
- Renaissance Technologies LLCexisting position · 83,862 shares now-36,820
- AllianceBernstein LPexisting position · 21,912 shares now-13,783
New positions and exits
New (2)
Exited (1)
- Balyasny Asset Management LLCwas $38m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2016 | 1 | $6.5m | n.a. | n.a. |
| Q1 2017 | 1 | $6.7m | n.a. | n.a. |
| Q4 2017 | 2 | $14m | n.a. | n.a. |
| Q1 2018 | 3 | $128m | n.a. | n.a. |
| Q2 2018 | 3 | $421m | n.a. | n.a. |
| Q3 2018 | 5 | $410m | n.a. | n.a. |
| Q4 2018 | 4 | $194m | n.a. | n.a. |
| Q1 2019 | 1 | $208m | n.a. | n.a. |
| Q2 2019 | 2 | $182m | n.a. | n.a. |
| Q3 2019 | 1 | $145m | n.a. | n.a. |
| Q4 2019 | 2 | $160m | n.a. | n.a. |
| Q1 2020 | 2 | $119m | n.a. | n.a. |
| Q2 2020 | 3 | $259m | n.a. | n.a. |
| Q3 2020 | 3 | $311m | n.a. | n.a. |
| Q4 2020 | 2 | $234m | n.a. | n.a. |
| Q1 2021 | 4 | $281m | n.a. | n.a. |
| Q2 2021 | 2 | $67m | n.a. | n.a. |
| Q3 2021 | 1 | $18m | n.a. | n.a. |
| Q4 2021 | 1 | $19m | n.a. | n.a. |
| Q1 2022 | 1 | $22m | n.a. | n.a. |
| Q2 2022 | 2 | $21m | n.a. | n.a. |
| Q3 2022 | 2 | $14m | n.a. | n.a. |
| Q4 2022 | 4 | $204m | n.a. | n.a. |
| Q1 2023 | 9 | $384m | n.a. | n.a. |
| Q2 2023 | 5 | $589m | n.a. | n.a. |
| Q3 2023 | 6 | $579m | n.a. | n.a. |
| Q4 2023 | 5 | $820m | 2 | 2 |
| Q1 2024 | 8 | $1.1bn | 6 | 1 |
| Q2 2024 | 7 | $1.1bn | 3 | 4 |
| Q3 2024 | 6 | $788m | 2 | 4 |
| Q4 2024 | 6 | $1.1bn | 2 | 3 |
| Q1 2025 | 7 | $1.2bn | 3 | 3 |
| Q2 2025 | 6 | $961m | 2 | 4 |
| Q3 2025 | 9 | $1.3bn | 6 | 2 |
| Q4 2025 | 12 | $1.8bn | 15 | 13 |
| Q1 2026 | 10 | $2.2bn | 13 | 15 |
| Q2 2026 | 11 | $2.3bn | 18 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MDGL and LLY →MDGL and JNJ →MDGL and VRTX →Choose a stock to compare with MDGL →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MDGL, latest filings →Back to the 13F Explorer →